IDKmonitor^® Infliximab Total ADA ELISA Intended Use

The IDKmonitor^® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE^®) in the presence of infliximab in EDTA plasma and serum.

This assay allows a reliable determination of ADA even in the presence of infliximab; therefore, it is ideal for therapeutic drug monitoring when a measurable infliximab concentration is expected. For example, shortly after the last infusion.

In combination with the drug level determination, the IDKmonitor^® Infliximab Total ADA ELISA can help physicians monitor and optimize therapy early on.

Treating Chronic Inflammatory Diseases with Anti-TNFα Antibodies

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFα antibodies, which directly target the underlying inflammatory processes.

The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFα antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA). It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application.

The IDKmonitor^® Infliximab Total ADA ELISA is Health Canada Licensed.

Browse our other IDKmonitor^® Infliximab ELISAs.